Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Novo Nordisk A/S
NOVANovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Address: Novo Alle 1, Bagsvaerd, Denmark, 2880
Analytics
Objectif de Cours de WallStreet
142.92 USDRatio C/B
38.3356Rendement du dividende
1.05 %Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés NOVA
Analyse des dividendes NOVA
Croissance des dividendes sur 5 ans
62 %Croissance continue
4 annéesRatio de distribution Moyenne sur 5 ans
19 %Historique des dividendes NOVA
Valorisation des titres NOVA
financières NOVA
Résultats | 2019 | Dynamique |